The full results, published in a recent issue of The New England Journal of Medicine, 1 build upon advances in genetic testing, biomarkers, nuclear imaging, and combination treatments for prostate cancer (PC). Moreover, the treatment had no unexpected or concerning safety signals. In June, at ASCO 2021, Novartis elaborated that the addition of LuPSMA, a theranostic, significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) compared with best standard of care alone. In March 2021, Novartis announced that the VISION trial (NCT03511664), which tested the efficacy and safety of lutetium (Lu)-177 PSMA-617 (LuPSMA) in treating men with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC), had met both of its primary end points.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |